Open Access iconOpen Access

ARTICLE

crossmark

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

YI-NONG CHEN1,#, YING-LIN CHEN1,#, WAN-MING CHEN2,3, MINGCHIH CHEN2,3, BEN-CHANG SHIA2,3, JENQ-YUH KO1,4, SZU-YUAN WU2,3,5,6,7,8,9,10,11,*

1 Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
2 Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan
3 Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan
4 Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
5 Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
6 Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
7 Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
8 Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan
9 Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
10 Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
11 Department of Management, College of Management, Fo Guang University, Yilan, Taiwan

* Corresponding Author: Szu-Yuan Wu, email
# These authors have contributed equally to this study (joint primary authors)

Oncology Research 2023, 31(1), 23-34. https://doi.org/10.32604/or.2022.028449

Abstract

This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384 patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users (adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of HNC in T2DM patients.

Keywords


Cite This Article

APA Style
CHEN, Y., CHEN, Y., CHEN, W., CHEN, M., SHIA, B. et al. (2023). H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus. Oncology Research, 31(1), 23-34. https://doi.org/10.32604/or.2022.028449
Vancouver Style
CHEN Y, CHEN Y, CHEN W, CHEN M, SHIA B, KO J, et al. H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus. Oncol Res. 2023;31(1):23-34 https://doi.org/10.32604/or.2022.028449
IEEE Style
Y. CHEN et al., "H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus," Oncol. Res., vol. 31, no. 1, pp. 23-34. 2023. https://doi.org/10.32604/or.2022.028449



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1210

    View

  • 512

    Download

  • 0

    Like

Related articles

Share Link